Evidence map›Paper›PMID 41539725›Full record

ArticleThe Journal of rheumatology2026

Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.

Rebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, Julie R Brahmer, Elena Ghotbi, Durrant Barasa, Clifton O Bingham, Ami A Shah, Laura C Cappelli

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rebecca FitzpatrickR. Fitzpatrick, MD, C.O. Bingham III, MD, A.A. Shah, MD, MHS, L.C. Cappelli, MD, MHS, MS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore.
Shadpour DemehriS. Demehri, MD, E. Ghotbi, MD, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore.
Joseph MurrayJ. Murray, MD, PhD, J.R. Brahmer, MD, MSc, D. Barasa, MB ChB, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Julie R BrahmerJ. Murray, MD, PhD, J.R. Brahmer, MD, MSc, D. Barasa, MB ChB, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Elena GhotbiS. Demehri, MD, E. Ghotbi, MD, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore.
Durrant BarasaJ. Murray, MD, PhD, J.R. Brahmer, MD, MSc, D. Barasa, MB ChB, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Clifton O BinghamR. Fitzpatrick, MD, C.O. Bingham III, MD, A.A. Shah, MD, MHS, L.C. Cappelli, MD, MHS, MS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore.
Ami A ShahR. Fitzpatrick, MD, C.O. Bingham III, MD, A.A. Shah, MD, MHS, L.C. Cappelli, MD, MHS, MS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore.
Laura C CappelliR. Fitzpatrick, MD, C.O. Bingham III, MD, A.A. Shah, MD, MHS, L.C. Cappelli, MD, MHS, MS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore; lcappel1@jhmi.edu.

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Antony Rosen · 2016 to 2026
$8.9M
Effect of statin intake on Non-traumatic Generalized Knee OsteoarthritisR01AR079620 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI DEMEHRI, SHADPOUR · 2021 to 2025
$1.8M
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
Evaluating the relationship between immune checkpoint inhibitors and osteoarthritisR03AR081997 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CAPPELLI, LAURA CHRISTINE · 2023 to 2024
$164k
NIAMS NIH HHS K24 AR080217NIAMS NIH HHS P30 AR070254NIAMS NIH HHS R01 AR079620NIAMS NIH HHS R03 AR081997
6 · The paper itself

Abstract

objectiveTo evaluate whether hip osteoarthritis (OA) is a risk factor for immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (ICI-IA).

methodsPatients treated for thoracic cancer with ICI therapy and with computed tomography (CT) of the abdomen/pelvis within 1 month of ICI start were included; hip OA was graded from a coronal slice of the CT by a radiologist. Chart review determined the presence of ICI-IA and other immune-related adverse events. Those with Kellgren-Lawrence grade of ≥ 2 in either hip on CT abdomen/pelvis were classified as having hip OA. Incidence rates of ICI-IA were calculated in patients with and without hip OA. Development of ICI-IA and overall survival were compared by Kaplan-Meier curves and Cox proportional hazards.

resultsA total of 309 patients were included; 103 had hip OA on CT scan. Overall, the cumulative incidence of ICI-IA was 54.8/1000 person-years and did not significantly differ between those with and without hip OA (

conclusionCT-derived hip OA was not significantly associated with development of ICI-IA in this cohort of patients with lung cancer. ICI-IA was associated with decreased mortality.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsOsteoarthritis, HipAgedFemaleHumansIncidenceMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesRisk FactorsTomography, X-Ray ComputedImmune Checkpoint Inhibitorsarthritisinflammationosteoarthritis

Identifiers

PMID41539725
PMCPMC12818542

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.